12:00 AM
 | 
Dec 17, 2007
 |  BioCentury  |  Product Development

Revlimid vs. Velcade

Revlimid vs. Velcade

Revlimid vs. Velcade
At last week's ASH meeting, Celgene (CELG) and Millennium (MLNM) each presented data from multiple Phase III trials of Revlimid and Velcade, respectively, for front-line treatment of multiple myeloma (MM). While the variety of treatment regimens, patient populations and milestones make head-to-head comparisons difficult, the significant results achieved in the trials suggest that doctors will have two...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >